Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117

Publication Date:
2018-09-04
Publisher:
Rockefeller University Press
Print ISSN:
0022-1007
Electronic ISSN:
1540-9538
Topics:
Medicine
Keywords:
Infectious Disease and Host Defense
Published by:
http://www.rupress.org/
_version_ 1836399042439938049
autor Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
beschreibung A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q 2 VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q 2 VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.
citation_standardnr 6327530
datenlieferant ipn_articles
feed_id 96
feed_publisher Rockefeller University Press
feed_publisher_url http://www.rupress.org/
insertion_date 2018-09-04
journaleissn 1540-9538
journalissn 0022-1007
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher Rockefeller University Press
quelle Journal of Experimental Medicine
relation http://jem.rupress.org/cgi/content/short/215/9/2311?rss=1
schlagwort Infectious Disease and Host Defense
search_space articles
shingle_author_1 Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
shingle_author_2 Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
shingle_author_3 Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
shingle_author_4 Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
shingle_catch_all_1 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
Infectious Disease and Host Defense
A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q 2 VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q 2 VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.
Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
Rockefeller University Press
0022-1007
00221007
1540-9538
15409538
shingle_catch_all_2 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
Infectious Disease and Host Defense
A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q 2 VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q 2 VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.
Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
Rockefeller University Press
0022-1007
00221007
1540-9538
15409538
shingle_catch_all_3 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
Infectious Disease and Host Defense
A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q 2 VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q 2 VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.
Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
Rockefeller University Press
0022-1007
00221007
1540-9538
15409538
shingle_catch_all_4 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
Infectious Disease and Host Defense
A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q 2 VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q 2 VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.
Cohen, Y. Z., Lorenzi, J. C. C., Krassnig, L., Barton, J. P., Burke, L., Pai, J., Lu, C.-L., Mendoza, P., Oliveira, T. Y., Sleckman, C., Millard, K., Butler, A. L., Dizon, J. P., Belblidia, S. A., Witmer-Pack, M., Shimeliovich, I., Gulick, R. M., Seaman, M. S., Jankovic, M., Caskey, M., Nussenzweig, M. C.
Rockefeller University Press
0022-1007
00221007
1540-9538
15409538
shingle_title_1 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
shingle_title_2 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
shingle_title_3 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
shingle_title_4 Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
timestamp 2025-06-30T23:36:41.168Z
titel Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
titel_suche Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
topic WW-YZ
uid ipn_articles_6327530